Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Growth in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant increase in short interest in February. As of February 15th, there was short interest totalling 78,500 shares, an increase of 102.8% from the January 31st total of 38,700 shares. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is presently 3.1 days. Currently, 0.7% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Maxim Group dropped their price objective on Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Indaptus Therapeutics Trading Up 6.8 %

Shares of INDP stock traded up $0.05 during midday trading on Friday, reaching $0.84. 4,970 shares of the stock were exchanged, compared to its average volume of 60,980. The company’s 50 day moving average is $0.87 and its two-hundred day moving average is $1.14. Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a market cap of $11.85 million, a PE ratio of -0.49 and a beta of 1.46.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.